The causes of such major discrepancies in the number of death “cases among different vaccines should be the focus of honest scientific and public discussion,” it added.
Both Pfizer and AstraZeneca were yet to react to the Sputnik V study.
In January, 23 elderly patients reportedly died in Norway following their immunization with the Pfizer-BioNTech mRNA vaccine against Covid-19.
On the other hand, several countries have halted the use of AstraZeneca as the shot may have caused some recipients to develop blood clots.
Recently, the regional health authorities in Italy’s Lombardy region have said that public confidence in the country’s use of the AstraZeneca Covid-19 vaccine has been hindered by the jab’s safety fears.
This week, the Therapeutic Goods Administration (TGA), Australia’s medical regulator, has ruled that a 48-year-old woman’s death due to blood clotting was a side effect of the AstraZeneca coronavirus vaccine.
Meanwhile, Hyderabad-based pharmaceutical major Dr. Reddy’s Laboratories (DRL) has received permission from the Drugs Controller General of India (DCGI) to import the Sputnik V vaccine in India for restricted use in emergencies.
After Covishield and Covaxin, Sputnik V, developed by the Gamaleya National Research Institute of Epidemiology and Microbiology in Moscow, is now the third Covid-19 vaccine to get emergency use approval in India.
This week, the Gamaleya National Research Center of Epidemiology and Microbiology and the Russian Direct Investment Fund (RDIF) reported that the Sputnik V Covid-19 vaccine showed a 97.6 per cent efficacy.